BioView, Transgenomic combine for in-vitro distribution pact:
This article was originally published in Clinica
Rehovot, Israel-based cell imaging specialist BioView is expanding its European sales penetration by combining with biotechnology company Transgenomic to distribute its scanning and analysis workstations in western Europe and Scandinavia. BioView's products, including its Duet, Allegro and Accord automated workstations, will be marketed, sold and serviced through Transgenomic's European sales force. BioView had previously sold its Duet system to university hospitals and commercial laboratories in the US and Europe through its own sales force. The company's automated scanning microscopes and image analysis systems are designed for in-vitro diagnostic use - particularly to aid the detection, classification and counting of cells for haematological, breast cancer, bladder cancer, and prenatal and postnatal genetic testing. Transgenomic (Omaha, Nebraska) said that the deal proved to be complementary to its existing line of cytogenetics products for genetic variation and mutation analysis. Financial terms of the deal were not disclosed.
You may also be interested in...
Diagnostics company Bodysphere had to retract an announcement that it had received an emergency use authorization from the US FDA for a COVID-19 serologic test. See why Bethany Hills, an attorney with law firm Morrison & Foerster, says this may be a cautionary tale for other manufacturers.
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Japanese ICT giant applies novel advanced computing techniques with a US venture partner to more rapidly identify lead molecules from a huge virtual space.